After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Ypsomed announced today that it agreed to sell its diabetes care business to TecMed for up to approximately $517.7 million ...

A Japanese hospital said Monday it has completed a clinical test to transplant induced pluripotent stem cells that produce insulin to treat a patient with type 1 diabetes, in a step that could ease ...

This allows us to explore the impact of different types of insulin and dietary management on blood sugar levels. Simulation results confirm the correctness of our proposed model and the effectiveness ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) has received U.S. FDA approval for the treatment of adult patients with generalized myasthenia ...

(NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® Hytrulo prefilled syringe for self-injection (efgartigimod alfa ...

Argenx (ARGX) announced that the U.S. Food and Drug Administration approved a new option for patients to self-inject VYVGART Hytrulo with a prefilled syringe for the treatment of adult patients ...